528 related articles for article (PubMed ID: 22971163)
1. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Hemachandran S; Al-Mezaine HS; Kangave D; Al-Muammar AM
Acta Ophthalmol; 2012 Dec; 90(8):e603-8. PubMed ID: 22971163
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Dosari M; Hemachandran S; Gikandi PW; Al-Muammar A
Acta Ophthalmol; 2017 Feb; 95(1):85-90. PubMed ID: 27535102
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids.
Abu El-Asrar AM; Al Tamimi M; Hemachandran S; Al-Mezaine HS; Al-Muammar A; Kangave D
Acta Ophthalmol; 2013 Sep; 91(6):e486-93. PubMed ID: 23575246
[TBL] [Abstract][Full Text] [Related]
4. Retinal vessel oxygen saturation is affected in uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; AlBloushi AF; Gikandi PW; Hardarson SH; Stefánsson E
Br J Ophthalmol; 2019 Dec; 103(12):1695-1699. PubMed ID: 30798260
[TBL] [Abstract][Full Text] [Related]
5. The effect on choroidal changes of the route of systemic corticosteroids in acute Vogt-Koyanagi-Harada disease.
Park UC; Cho IH; Lee EK; Yu HG
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1203-1211. PubMed ID: 28382438
[TBL] [Abstract][Full Text] [Related]
6. Clinical features and visual outcomes of 111 patients with new-onset acute Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids.
Nakayama M; Keino H; Watanabe T; Okada AA
Br J Ophthalmol; 2019 Feb; 103(2):274-278. PubMed ID: 29666121
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Vogt-Koyanagi-Harada Disease: A Subanalysis From a Randomized Clinical Trial of Antimetabolite Therapies.
Shen E; Rathinam SR; Babu M; Kanakath A; Thundikandy R; Lee SM; Browne EN; Porco TC; Acharya NR
Am J Ophthalmol; 2016 Aug; 168():279-286. PubMed ID: 27296490
[TBL] [Abstract][Full Text] [Related]
8. The outcomes of indocyanine green angiography monitored immunotherapy in Vogt-Koyanagi-Harada disease.
Chee SP; Jap A
Br J Ophthalmol; 2013 Feb; 97(2):130-3. PubMed ID: 23212203
[TBL] [Abstract][Full Text] [Related]
9. Chronic Recurrent Vogt-Koyanagi-Harada Disease and Development of 'Sunset Glow Fundus' Predict Worse Retinal Sensitivity.
Abu El-Asrar AM; Al Mudhaiyan T; Al Najashi AA; Hemachandran S; Hariz R; Mousa A; Al-Muammar A
Ocul Immunol Inflamm; 2017 Aug; 25(4):475-485. PubMed ID: 27003480
[TBL] [Abstract][Full Text] [Related]
10. A case of probable Vogt-Koyanagi-Harada disease in a 3-year-old girl.
Katsuyama A; Kusuhara S; Awano H; Nagase H; Matsumiya W; Nakamura M
BMC Ophthalmol; 2019 Aug; 19(1):179. PubMed ID: 31409322
[TBL] [Abstract][Full Text] [Related]
11. Clinical Outcomes of Patients with Vogt-Koyanagi-Harada Disease Over 12 Years at a Tertiary Center.
Arevalo JF; Lasave AF; Gupta V; Kozak I; Al Harbi MB; Al Rushood AA; Al Dhibi HA
Ocul Immunol Inflamm; 2016 Oct; 24(5):521-9. PubMed ID: 26399962
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Clinical Features and Visual Outcome between Sympathetic Ophthalmia and Vogt-Koyanagi-Harada Disease in Chinese Patients.
Yang P; Liu S; Zhong Z; Du L; Ye Z; Zhou W; Kijlstra A
Ophthalmology; 2019 Sep; 126(9):1297-1305. PubMed ID: 30959067
[TBL] [Abstract][Full Text] [Related]
13. Novel treatment regimen of Vogt-Koyanagi-Harada disease with a reduced dose of corticosteroids combined with immunosuppressive agents.
Yang P; Ye Z; Du L; Zhou Q; Qi J; Liang L; Wu L; Wang C; Kijlstra A
Curr Eye Res; 2018 Feb; 43(2):254-261. PubMed ID: 29111815
[TBL] [Abstract][Full Text] [Related]
14. Retinal functional changes measured by microperimetry after immunosuppressive therapy in patients with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Al-Mezaine HS; Hemachandran S; Hariz R; Kangave D
Eur J Ophthalmol; 2012; 22(3):368-75. PubMed ID: 21928252
[TBL] [Abstract][Full Text] [Related]
15. Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt-Koyanagi-Harada disease.
Urzua CA; Velasquez V; Sabat P; Berger O; Ramirez S; Goecke A; Vásquez DH; Gatica H; Guerrero J
Acta Ophthalmol; 2015 Sep; 93(6):e475-80. PubMed ID: 25565265
[TBL] [Abstract][Full Text] [Related]
16. High rate of clinical recurrence in patients with Vogt-Koyanagi-Harada disease treated with early high-dose corticosteroids.
Sakata VM; da Silva FT; Hirata CE; Marin ML; Rodrigues H; Kalil J; Costa RA; Yamamoto JH
Graefes Arch Clin Exp Ophthalmol; 2015 May; 253(5):785-90. PubMed ID: 25592477
[TBL] [Abstract][Full Text] [Related]
17. Comparison of two different combination immunosuppressive therapies in the treatment of Vogt-Koyonagi-Harada syndrome.
Arcinue CA; Radwan A; Lebanan MO; Foster CS
Ocul Immunol Inflamm; 2013; 21(1):47-52. PubMed ID: 23323581
[TBL] [Abstract][Full Text] [Related]
18. Vogt-Koyanagi-Harada Disease Managed With Immunomodulatory Therapy Within 3 Months of Disease Onset.
Ei Ei Lin Oo ; Chee SP; Wong KKY; Hla Myint Htoon
Am J Ophthalmol; 2020 Dec; 220():37-44. PubMed ID: 32738228
[TBL] [Abstract][Full Text] [Related]
19. Indocyanine green angiography-guided management of Vogt-Koyanagi-Harada disease: differentiation between choroidal scars and active lesions.
Knecht PB; Mantovani A; Herbort CP
Int Ophthalmol; 2013 Oct; 33(5):571-7. PubMed ID: 23277207
[TBL] [Abstract][Full Text] [Related]
20. Corticotherapy vs. Corticotherapy Plus Immunosuppressive Therapy in Acute Vogt-Koyanagi-Harada Disease.
Concha-Del Río LE; Gómez L; Arellanes-García L
Arch Soc Esp Oftalmol (Engl Ed); 2018 May; 93(5):225-230. PubMed ID: 29258782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
